Kytopen

company

About

Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.

  • 11 - 50

Details

Last Funding Type
Non-Equity Assistant
Industries
Biotechnology,Genetics,Health Care,Life Science
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Kytopen is a developer of a cell therapy platform designed for non-viral delivery of molecules into hard-to-transfect immune cells. The company's technology combines microfluidics and automation to make non-viral delivery of molecules easier, faster and cheaper through an automated cell engineering platform, enabling researchers to find new discoveries in biology that will lead to cost effective cell and gene therapies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$31.21M
Kytopen has raised a total of $31.21M in funding over 2 rounds. Their latest funding was raised on Sep 28, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 28, 2021 Series A $30M 1 Detail
Dec 8, 2020 Angel $195K 1 Detail
Mar 1, 2019 Grant $798.46K 1 National Science Foundation Detail
Feb 4, 2019 Non-Equity Assistant 1 Detail
Dec 21, 2017 Grant $225K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
2
3
Kytopen is funded by 3 investors. National Science Foundation and TBD Angels are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant
TBD Angels Series A
Merck Non-Equity Assistant